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Abstract 40 
There is debate regarding the value of vaccinating adults with the 13-valent pneumococcal 41 
conjugate vaccine (PCV-13). This analysis was conducted to investigate the risk of PCV-13 42 
serotype community acquired pneumonia (CAP) in hospitalised adults with co-morbid disease 43 
and risk factors for pneumococcal disease in the UK.  44 
 45 
Consecutive adults hospitalised (2008 - 2013) with a primary diagnosis of CAP, were recruited. 46 
Pneumococcal aetiology disease was identified by use of pneumococcal urinary antigen 47 
detection and serotype identification using a validated multiplex immunoassay or serum latex 48 
agglutination. Adults with PCV-13 serotype CAP were compared to those with non-PCV-13 49 
serotype CAP.    50 
 51 
Of 2224 patients, PCV-13 serotype CAP was identified in 337 (15.2%) and non-PCV-13 serotype 52 
CAP in 250 (11.2%) individuals. Adults aged ≥65 years with one or more clinical risk factors had a 53 
significantly lower risk of PCV-13 serotype CAP compared to those aged 16-64 years without 54 
clinical risk factors (aOR 0.61, 95%CI 0.41-0.92, p=0.018). In a stacked-risk analysis, the presence 55 
of incremental clinical risk factors was associated with lower odds of PCV-13 disease (p for trend 56 
4 
= 0.029) Adults with underlying chronic respiratory disease (aOR) 0.56, 95% CI 0.36-0.85, 57 
p=0.007) and chronic kidney disease (aOR 0.48, 95% CI 0.25-0.92, p=0.028) had significantly lower 58 
adjusted odds of PCV-13 compared to non-PCV-13 serotype CAP.  59 
 60 
This analysis suggests that in the UK, the burden of PCV13 disease is greater in adults outside the 61 
traditional ‘at-risk’ groups compared to adults in ‘at-risk’ groups.  62 
 63 
5 
Introduction 64 
Increasing age and the presence of co-morbid diseases are recognised risk factors for 65 
pneumococcal disease.1-4 In addition, pneumococcal attributable mortality is higher in these 66 
clinical risk groups.5 6  Therefore, implementation of appropriate vaccination strategies is 67 
important for these individuals. The current UK vaccination policy recommends 23-valent 68 
polysaccharide pneumococcal vaccination (PPV-23) in adults at high risk of pneumococcal 69 
disease, comprising (a) adults aged between 16-64 years with certain co-morbid diseases, and (b) 70 
adults aged 65 years and over.7 However, polysaccharide vaccine effectiveness in these risk 71 
groups is debated.8-12 Immunogenicity studies have shown higher antibody concentrations and 72 
functional antibody responses to pneumococcal conjugate compared with polysaccharide 73 
vaccination in adults at higher risk of pneumococcal disease including those with human 74 
immunodeficiency virus (HIV), chronic obstructive pulmonary disease and older adults.13-15  75 
Therefore, such patients may benefit from the administration of pneumococcal conjugate 76 
vaccination (PCV) in addition to, or in place of the current polysaccharide vaccine. In randomised 77 
controlled trials in Malawi and the Netherlands, administration of the pneumococcal conjugate 78 
vaccine reduced vaccine-type (VT) invasive pneumococcal disease (IPD) and community acquired 79 
pneumonia (CAP) in risk groups of immunocompromised adults with HIV and those over the age 80 
of 65 years, respectively.16 17 However, any assessment of the benefits of vaccinating adults with 81 
the conjugate vaccine needs to take into account the burden of VT disease in the target group. 82 
In the UK, there has been a substantial decrease in adult pneumococcal VT disease as a 83 
consequence of herd protection following the introduction of the infant pneumococcal 84 
vaccination programme; this decrease is apparent for both invasive and non-invasive 85 
6 
pneumococcal disease.18-21 In patients with IPD, these herd effects appear similar among patients 86 
with and without clinical risk factors for pneumococcal disease.3 There are no such relevant data 87 
in adults with non-invasive pneumococcal pneumonia.   88 
 89 
In this study, we sought to determine whether hospitalised individuals at high risk of 90 
pneumococcal disease are more likely to have PCV-13 serotype CAP compared to non-PCV-13 91 
serotype CAP.  92 
7 
Methods 93 
Study design 94 
We conducted a prospective cohort study of consecutive adult patients admitted, with a primary 95 
diagnosis of community acquired pneumonia, to two large university hospitals in Nottingham, 96 
between September 2008 and 2013. Combined, these two hospitals cover the catchment area 97 
for acute and emergency admissions in the Greater Nottingham area. All patients admitted to 98 
medical admissions units were screened every weekday, using radiological and clinical records, 99 
to assess for study eligibility. Study eligible patients were aged 16 years or over, presenting with 100 
symptoms of a lower respiratory tract infection (at least one of: cough, increasing breathlessness, 101 
sputum production and fever), who had radiographic infiltrates consistent with respiratory 102 
infection, and who were treated by their clinical team for a diagnosis of CAP. Adults hospitalised 103 
in the 10 days preceding the index admission or who had a diagnosis of tuberculosis or post-104 
obstructive pneumonia were excluded. Informed consent was obtained from all study patients; 105 
in the event that patients lacked capacity, patient personal consultees were approached for proxy 106 
consent. Patient demographics and clinical details were collected from patient records. All study 107 
procedures were approved by Nottingham Research Ethics Committee. 108 
 109 
Study population 110 
Routine microbiological investigations were performed at the discretion of the clinical team. In 111 
addition, urine samples were taken on admission from each individual for pneumococcal specific 112 
microbiological analysis; Binax-NOW® assays were performed for pneumococcal C-113 
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polysaccharide urinary antigen detection (UAD) at the local microbiological laboratories whilst 114 
the remaining volume of urine was frozen and batch transported to Public Health England (PHE)’s 115 
Respiratory and Vaccine Preventable Bacteria Reference Unit in Colindale for serotyping of 116 
pneumococcal strains by a multiplex immunoassay (Bio-plex). The Bio-plex assay was validated 117 
for detection of pneumococcal serotypes 1, 3, 4, 5, 6A/C, 6B, 7F/A, 8, 9V, 14, 18, 19A, 19F and 118 
23F.22 The sensitivity and specificity for pneumococcal detection using the Binax-NOW® method, 119 
is 74% and 97%, respectively and for the Bio-plex method, is 79% and 99%, respectively.22 23 120 
Bacteraemic cases of CAP due to Streptococcus pneumoniae were identified and serotyped by 121 
serum latex agglutination at PHE’s reference laboratory. Patients were considered to have 122 
pneumococcal CAP if any of the following criteria were met: (a) a positive pneumococcal UAD, or 123 
(b) a positive blood culture for S pneumoniae, or (c) pneumococcal serotype detection by the Bio-124 
plex assay.   125 
 126 
Statistical considerations 127 
Statistical analyses were performed using Stata/IC 13.1 (©StataCorp., 2013). Serotypes were 128 
grouped into PCV-7 types (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F), ‘additional’ PCV-13 types 129 
not present in PCV-7 (serotypes 1, 3, 5, 6A/C, 7F/A, 19A) and ‘other’ non-PCV-13 serotypes. PCV-130 
13 disease was defined as the identification of one or more of serotypes in either the PCV-7 or 131 
‘additional’ PCV-13 groups. Non-PCV-13 disease was defined as the isolation of any other 132 
pneumococcal serotype or the presence of ‘untyped’ non-invasive pneumococcal CAP (based on 133 
a positive UAD). Baseline characteristics and putative co-morbid disease risk factors for PCV-13 134 
disease were compared using Pearson’s chi-square or Fisher’s tests for categorical variables, and 135 
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the Mann Whitney U-test for non-parametric continuous variables. The independent association 136 
between baseline co-morbidity and PCV-13 disease compared to non-PCV-13 disease was 137 
examined using a multivariable logistical regression model; those co-morbid diseases with a p 138 
value of < 0.2 on univariate analysis were included in the multivariable model. Likelihood ratio 139 
tests were used to determine the best model fit for continuous variables. Secondary analysis 140 
were conducted examining the odds of PCV-13 disease in (a) all ‘at-risk’ individuals (defined as 141 
those aged 16-64 with a clinical risk factor for pneumococcal disease or those ≥ 65 years), (b) 142 
individuals stratified according to age (dichotomised at 65 years) and the presence of a clinical 143 
risk factor for pneumococcal disease: (1) aged 16-64 years without a clinical risk factor, (2) aged 144 
16-64 years with one or more clinical risk factors, (3) aged ≥65 years without a clinical risk factor, 145 
(4) aged ≥65 years with one or more clinical risk factors and (c) individuals with increasing 146 
numbers of clinical risk factors; gender was included a priori in these models. Clinical risk factors 147 
for pneumococcal disease were defined as those eligible for pneumococcal vaccination in the UK 148 
as described in PHE’s ‘Immunisation against Infectious Diseases’; in brief, risk factors included 149 
chronic respiratory disease, chronic heart disease, chronic kidney disease, chronic liver disease, 150 
immunosuppression, diabetes, splenic dysfunction and individuals with cerebrospinal fluid (CSF) 151 
leaks or cochlear implants.7 Immunosuppression was defined as the presence of splenic 152 
dysfunction, haematological disease including malignancy, solid organ or bone marrow 153 
transplant, immunodeficiency, treatment with immunosuppressive medication (not including 154 
steroids) or HIV; all other case definitions were derived from a previous study examining clinical 155 
risk groups in pneumococcal disease.24  156 
 157 
10 
Incidence data for pneumococcal CAP in the Greater Nottingham area were calculated using data 158 
on population demographics collected from (a) the National Infection Service, PHE, for adults 159 
aged 16-64 with clinical risk factors,  and (b) the UK census (2011) for adults aged ≥ 65 years.25 160 
As there is no national registry of risk groups for pneumococcal disease, population demographic 161 
data for influenza risk groups were taken as a surrogate measure for incidence calculations.26 162 
 163 
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Results 164 
Study population 165 
Over the 5 year study period, 2702 patients were eligible for study inclusion. Of these, 284 166 
(10.5%) were subsequently found to have an alternative diagnosis to CAP and in a further 194 167 
patients, study consent was not obtained. The final study cohort consisted of 2224 adults. 168 
Patients in whom consent was not obtained were older (median age: 82 years, IQR 73-89 years 169 
versus 71 years, IQR 56-80 years, p<0.001) and were more likely to have chronic kidney disease 170 
(13.4% versus 7.6%, p=0.004), cerebrovascular disease (21.8% versus 9.1%, p<0.001) and 171 
dementia (33.5% versus 2.0%, p<0.001) compared to patients in the study cohort. They were also 172 
less likely to have chronic respiratory disease (14.4% versus 25.7%, p<0.001). No other biases in 173 
co-morbid diseases were observed.  174 
Pneumococcal CAP was diagnosed in 643 of 2224 (28.9%) individuals. Urine was unavailable for 175 
serotype analysis in 56 (8.7%) of 643 cases.  One or more serotypes were identified in 429 (66.7%) 176 
of 643 cases of pneumococcal CAP; the remainder represent untyped cases of pneumococcal 177 
CAP.   Cases where urine was unavailable for serotyping were excluded from analysis of the 178 
association of clinical risk group and PCV-13 disease.   179 
 180 
Baseline characteristics 181 
Of 643 patients with pneumococcal CAP, 294 (45.7%) had one or more clinical risk factors for 182 
pneumococcal disease; of these, chronic respiratory disease (n=130, 44.2%) and chronic heart 183 
disease (n=124, 42.2%) represented the majority of cases.  There were 68 patients (10.6%) aged 184 
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16-64 years with a clinical risk factor and 377 (58.6%) patients were aged ≥ 65 years. Three 185 
hundred and forty nine (54.3%) patients with pneumococcal disease had no underlying clinical 186 
risk factor for pneumococcal disease; one clinical risk factor was present in 205 (31.9%) patients, 187 
two clinical risk factors were present in 62 (9.6%) patients and three or more clinical risk factors 188 
were present in 27 (4.2%).  Diabetes (9.8%) and chronic respiratory disease (8.7%) represented 189 
the most common co-morbid diseases amongst patients aged 16-64 years, whilst chronic heart 190 
disease (29.2%) and chronic respiratory disease (28.4%) were the most common co-morbid 191 
diseases amongst those aged ≥ 65 years (Table 1).  There were no patients with cochlear implants 192 
or CSF fluid leaks. 193 
 194 
Clinical risk groups and PCV-13 disease 195 
Of 587 pneumococcal CAP cases where a urine was available for serotype identification, PCV-13 196 
and non-PCV-13 disease comprised 337 (57.4%) and 250 (42.6%) cases respectively. Baseline 197 
characteristics of patients with PCV-13 and non-PCV-13 serotype CAP are shown in (Table 2). 198 
Patients with underlying chronic respiratory disease and chronic kidney disease had significantly 199 
lower odds of PCV-13 disease compared to non-PCV-13 disease (adjusted Odds Ratio (aOR) 0.56, 200 
95% CI 0.36-0.85, p=0.007, and aOR 0.48, 95%CI 0.25-0.92, p=0.028, respectively). Conversely, 201 
those with dementia had significantly higher odds of PCV-13 disease (aOR 3.91, 95%CI 1.10-202 
13.91, p=0.036). 203 
 204 
Of patients with pneumococcal CAP, 184 (31.4%) were aged 16-64 years with no clinical risk 205 
factors, 57 (9.7%) were aged 16-64 years with one or more clinical risk factors, 133 (22.7%) were 206 
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aged ≥65 years with no clinical risk factors and 213 (36.3%) were aged ≥65 years with one or 207 
more clinical risk factors. In the gender-adjusted model, patients aged ≥65 years with one or 208 
more clinical risk factors had a significantly lower risk of PCV-13 serotype CAP compared to those 209 
aged 16-64 years without clinical risk factors (aOR 0.61, 95%CI 0.41-0.92, p=0.018) (Table 3). In a 210 
stacked-risk analysis adjusted for gender and age, the presence of incremental clinical risk factors 211 
was associated with lower odds of PCV-13 disease (Figure 1). The gender-adjusted odds of PCV-212 
13 disease was lower in patients that comprised the total ‘at-risk’ group (those aged 16-64 years 213 
with clinical risk factors or those aged ≥65 years): aOR 0.71, 95%CI 0.49-1.02, p=0.062. 214 
 215 
Serotype distribution of pneumococcal CAP by risk group  216 
Table 4 shows the distribution of single serotypes with >10 isolates. Serotypes 7F/A and 8 were 217 
the most common, both being isolated in 69 patients. Using serotype 8 as reference, serotypes 218 
3, 5 and 14 were significantly associated with causing disease in ‘at-risk’ patients compared to 219 
those not at-risk whilst serotype 7F/A was associated with lower odds of disease in ‘at-risk’ 220 
patients. 221 
 222 
Incidence of pneumococcal CAP in clinical risk groups 223 
The overall incidence of pneumococcal CAP was 20.7 per 100, 000 persons whilst that of PCV-13 224 
CAP was 10.8 per 100,000 and non-PCV-13 CAP was 8.0 per 100,000. The highest overall 225 
incidence of pneumococcal CAP was observed in those over 65 years (64.3 per 100,00); in these 226 
patients the incidence of PCV-13 serotype CAP was 32.9 per 100,000 persons, and that of non-227 
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PCV-13 serotype CAP was 26.1per 100,000 persons. The incidence of PCV-13 and non-PCV-13 228 
pneumococcal CAP by clinical risk group is shown in Figure 2. Incidence rates of non-PCV-13 229 
serotype CAP was two to three fold that of PCV-13 serotype CAP in patients aged 16-64 years 230 
with chronic liver disease and those who were immunocompromised. Conversely, patients aged 231 
16-64 years with diabetes had a higher incidence of PCV-13 compared to non-PCV-13 serotype 232 
CAP (16.7 versus 5.6, per 100,000 persons). 233 
 234 
Mortality 235 
Overall, 30-day mortality in patients with pneumococcal CAP was 7.5%. Of those individuals ‘at-236 
risk’ of pneumococcal disease, 30-day pneumococcal CAP mortality was 10.3% compared to 1.0% 237 
in those under 65 years considered not at risk. The highest pneumococcal CAP mortality was 238 
observed in individuals ≥ 65 years with a clinical risk factor (14.2%), followed by those ≥ 65 years 239 
without a clinical risk factor (8.6%). For those under 65 years with a clinical risk factor, 30-day 240 
mortality was 1.5%. There was no significant difference in 30-day mortality in all individuals with 241 
PCV-13 compared to non-PCV-13 serotype CAP (8.3% vs 7.6%; OR 1.10, 95% CI 0.60-2.02, 242 
p=0.755), nor in those individuals classified as ‘at-risk’ (11.7% vs 10.5%; OR 1.13, 95% CI 0.60-243 
2.12, p=0.701). 244 
 245 
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Discussion 246 
In adults hospitalised with pneumococcal CAP, we found that PCV-13 serotype CAP was 44% less 247 
likely in patients with chronic respiratory disease and 52% less likely in chronic kidney disease 248 
compared to non-PCV-13 serotype CAP.  The odds of PCV-13 serotype CAP were significantly 249 
lower with increasing numbers of clinical risk factors for pneumococcal infection.  250 
 251 
These results are consistent with findings observed from studies in adult IPD, where PCV-13 252 
serotypes have been shown to be less frequently associated with the presence of underlying co-253 
morbid disease, compared to non-PCV-13 serotypes.5 27 28 Similarly, a 16-year cohort study 254 
demonstrated that individuals with chronic respiratory disease and chronic kidney disease were 255 
more likely to have non-vaccine type (NVT) (non-PCV-13 and non-PPV-23) IPD compared to PCV-256 
13 disease.28 However, in contrast to analyses in IPD cohorts which have shown an association 257 
with younger age and PCV-13 serotype disease, we observed no association between PCV-13 258 
serotype disease and age.5 28  259 
 260 
In the UK, introduction of the infant vaccination programme has been highly successful in 261 
reducing VT serotype IPD as a consequence of herd protection.18 29 30 Whether these reductions 262 
in VT disease equally apply to adults at clinical risk of pneumococcal disease as to other adults is 263 
less well defined.3 31 32 33 In addition, despite overall decreases in VT pneumococcal disease, 264 
increases in NVT IPD have been observed in at risk populations including the 265 
immunocompromised and those over 65 years.20 28 34 Our findings, involving mainly adults with 266 
16 
non-invasive CAP, adds to the evidence base that older adults with clinical risk factors are more 267 
likely to have non-PCV-13 serotype CAP compared to PCV-13 serotype CAP. Differences in the 268 
invasive potential of pneumococcal serotypes may provide a possible explanation for these 269 
observations; non-PCV-13 serotypes are generally less invasive compared to PCV-13 serotypes.27 270 
Consequently, non-PCV-13 serotypes may be more likely to act as opportunistic pathogens in 271 
older patients with co-morbid diseases.35-38  272 
 273 
Our finding that patients with dementia were much more likely to be hospitalised with CAP due 274 
to PCV-13 serotypes was dominated by patients with dementia who had PCV-7 serotype disease 275 
(11 of 19 patients) identified in the first 2 years of the study. Whilst social isolation and lack of 276 
child contact in patients with dementia might explain this finding, confirmation of this association 277 
in a different patient cohort is necessary.39  278 
 279 
In adults under 65 years, the presence of chronic liver disease or immunocompromise were 280 
associated with the highest incidence of pneumococcal CAP. Van Hoek et al linked UK IPD cases 281 
to Hospital Episode Statistics (HES) data to estimate incidence rates for clinical risk groups; they 282 
too demonstrated that the highest incidence of pneumococcal disease in this age group occurred 283 
in these conditions.3 The absolute incidence rates for each clinical risk factor were considerably 284 
lower in our study compared to that of Van Hoek et al and two similar population based IPD 285 
studies conducted in Finland and the Netherlands.3 6 26 Possible reasons for this difference include 286 
(a) the inclusion of infants and children in previous IPD studies and (b) incomplete recruitment 287 
of adults in certain high risk groups, to the current study.  288 
17 
 289 
Strengths and limitations of this analysis 290 
To our knowledge this is the first report to describe the relationship between clinical risk factors 291 
for pneumococcal disease and PCV-13 serotype CAP in adults.  A key strength of this study is the 292 
identification of pneumococcal serotypes in non-bacteraemic cases of CAP. The main limitation 293 
of the study was the inability to detect non-PCV-13 serotypes other than serotype 8 in patients 294 
with non-bacteraemic CAP. For the comparative analysis, patients with untyped pneumococcal 295 
CAP were considered to have non-PCV-13 serotype CAP. Although the Bio-plex assay has a high 296 
sensitivity for the detection of 14 serotypes, some patients with untyped pneumococcal CAP may 297 
have had PCV-13 serotype CAP; thus any differences identified between groups are likely to be 298 
conservative for the association with PCV-13 serotype disease. The overall proportion of study 299 
patients with dementia as a co-morbid illness was low in this study. Whilst this may be a true 300 
finding, we are unable to exclude temporal selection bias given the high prevalence of PCV-7 301 
serotypes and contemporaneous national data from the British Thoracic Society CAP audit which 302 
demonstrated an increase in the proportions of patients with dementia over the study period 303 
(the inverse of which was seen in the present study).40   304 
 305 
For incidence calculations, population level data on influenza risk groups from 2015/16 were used 306 
in place of pneumococcal clinical risk groups as a national registry of the latter is lacking.  307 
Influenza risk groups overlap with pneumococcal clinical risk groups, with the exception of 308 
cochlear implants and CSF leaks, the latter two of which had no study patients. The impact of this 309 
limitation on study results is likely to be small. Completeness of case ascertainment and 310 
18 
microbiological testing would also be expected to influence incidence calculations. A small 311 
proportion of patients admitted over weekends and with very short lengths of stay may not have 312 
been recruited to the study; urine samples were also not available for serotype analysis in 56 313 
(8.7%) patients with pneumococcal CAP. Therefore, incidence rate estimates are likely to be 314 
conservative.   315 
Implications of results 316 
Whilst PCV-13 vaccine efficacy against VT serotype pneumococcal pneumonia has been 317 
demonstrated in older adults, the effect of conjugate vaccine administration across other clinical 318 
risk groups remains uncertain.17  An important question for pneumococcal vaccine policy is 319 
whether there are identifiable groups of adults at risk of VT disease despite herd protection 320 
effects arising from pneumococcal vaccination programmes. We found that in the presence of a 321 
strong infant pneumococcal vaccination programme, the burden of PCV13 disease is greater in 322 
adults outside the traditional ‘at-risk’ groups compared to adults in ‘at-risk’ groups. Adults in the 323 
traditional ‘at-risk’ groups were more likely to be hospitalised with non-PCV-13 serotype CAP 324 
than PCV-13 serotype CAP. Offering PCV-13 vaccination to adults in clinical risk groups may 325 
therefore be of limited benefit in this setting. 326 
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22 
Table 1 – Distribution of co-morbid diseases in adults with pneumococcal CAP 
 
 
 
 
 
 
 
 
 
 
All values given as n (%) 
 
 
 
 
 
 
 
 16-64 years 
n=266 
≥65 years 
n=377 
Chronic heart disease 14 (5.3) 110 (29.2) 
Chronic respiratory disease  23 (8.7) 107 (28.4) 
Diabetes 26 (9.8) 56 (14.9) 
Chronic kidney disease 4 (1.5) 44 (11.7) 
Chronic liver disease 6 (2.3) 4 (1.1) 
Immunosuppressed 8 (3.0) 10 (2.7) 
Cancer 12 (4.5) 26 (6.9) 
Dementia 0 (0.0) 19 (5.0) 
Cerebrovascular disease 5 (1.9) 62 (16.5) 
23 
Table 2 - Clinical features of adults admitted with CAP and comparative analysis of those with PCV-13 versus non-PCV-13 serotype CAP 
  All cause CAP  Pneumococcal CAP OR (95%CI) p value 
 (n=2224) PCV-13 disease 
(n=337) 
Non-PCV-13 
disease (n=250) 
  
Age      
   16-49 years 431 (19.4) 86 (25.5) 58 (23.2) Reference 0.216Ɨ 
   50-64 years 424 (19.1) 58 (17.2) 39 (15.6) 1.00 (0.59-1.70)  
   65-74 years 468 (21.0) 75 (22.3) 44 (17.6) 1.15 (0.70-1.90)  
   75-84 years 577 (25.9) 67 (19.9) 72 (28.8) 0.63 (0.39-1.01)  
   ≥85 years 324 (14.6) 51 (15.1) 37 (14.8) 0.93 (0.54-1.59)  
Male 1225 (55.1) 180 (53.4) 115 (46.0) 1.35 (0.97-1.87) 0.076 
      
Care home resident¥ 92 (4.2) 15 (4.5) 13 (5.2) 0.86 (0.40-1.85) 0.702 
PPV23 vaccination¥ 931 (47.3) 123 (41.6) 108 (50.2) 0.70 (0.49-1.00) 0.052 
Smoking status¥      
   Never 612 (29.1) 82 (25.8) 64 (27.2) Reference 0.864Ɨ 
   Ex 989 (46.9) 144 (45.3) 97 (41.3) 1.16 (0.76-1.76)  
   Current 506 (24.0) 92 (28.9) 74 (31.5) 0.97 (0.62-1.52)  
Alcohol excess 47 (2.1) 9 (2.7) 7 (2.8) 0.95 (0.35-2.60) 0.924 
      
Chronic respiratory disease 572 (25.7) 52 (15.4) 66 (26.4) 0.51 (0.34-0.77) 0.001 
Asthma 267 (12.0) 40 (11.9) 39 (15.6) 0.73 (0.45-1.17) 0.191 
COPD 509 (22.9) 46 (13.7) 60 (24.0) 0.50 (0.33-0.77) 0.001 
Chronic heart disease 500 (22.5) 63 (18.7) 53 (21.2) 0.85 (0.57-1.29) 0.451 
CCF 146 (6.6) 19 (5.6) 15 (6.0) 0.94 (0.47-1.88) 0.853 
IHD 249 (11.2) 28 (8.3) 27 (10.8) 0.75 (0.43-1.31) 0.306 
Diabetes 305 (13.7) 48 (14.2) 26 (10.4) 1.43 (0.86-2.38) 0.166 
Chronic liver disease 24 (1.1) 5 (1.5) 5 (2.0) 0.74 (0.21-2.58) 0.751 
Chronic kidney disease 169 (7.6) 17 (5.0) 27 (10.8) 0.44 (0.23-0.83) 0.009 
Immunocompromised 82 (3.7) 6 (1.8) 8 (3.2) 0.55 (0.19-1.60) 0.265 
24 
All values expressed as n (%); Ɨ- p for trend; ¥- care home and smoking status unavailable for 26 and 117 patients, respectively. 
PPV23 – 23-valent pneumococcal polysaccharide vaccine (¥ data unavailable for 254 patients), COPD – chronic obstructive pulmonary 
disease, CCF – congestive cardiac failure, IHD – ischaemic heart disease. * - severely immunocompromised group consists of bone marrow 
transplant patients, patients with acute and chronic leukaemia, multiple myeloma or those with genetic disorders affecting the immune 
system 
OR and p values compare PCV-13 serotype disease to non-PCV-13 disease. 
 
 
 
 
Severely immunocompromised* 22 (1.0) 0 (0.0) 5 (2.0) - - 
Active malignancy 169 (7.6) 21 (6.2) 13 (5.2) 1.21 (0.59-2.47) 0.597 
Dementia 45 (2.0) 16 (4.8) 3 (1.2) 4.10 (1.17-14.34) 0.016 
Cerebrovascular disease 202 (9.1) 42 (12.5) 23 (9.2) 1.41 (0.82-2.41) 0.213  
     
Number of clinical risk factors:      
0 1078 (48.5) 198 (58.8) 119 (47.6) Reference 0.016Ɨ 
1 751 (33.8) 98 (29.1) 92 (36.8) 0.64 (0.44-0.92)  
2 289 (13.0) 30 (8.9) 26 (10.4) 0.69 (0.39-1.23)  
≥3 106 (4.8) 11 (3.3) 13 (5.2) 0.51 (0.22-1.18)  
      
Low severity (CURB65≤1) 1029 (46.3) 134 (39.8) 100 (40.0) Reference 0.732Ɨ 
Moderate severity (CURB65=2) 684 (30.8) 107 (31.8) 84 (33.6) 0.95 (0.65-1.40)  
High severity (CURB65≥3) 511 (23.0) 96 (28.5) 66 (26.4) 1.09 (0.72-1.63)  
      
30-day mortality 230 (10.3) 28 (8.3) 19 (7.6) 1.10 (0.60-2.02) 0.755 
25 
 
 
 
Table 3 – Association between clinical risk group and PCV-13 disease  
 aOR (95% CI) p value 
16-64 yrs with no clinical risk 
factor 
Reference - 
16-64 yrs with clinical risk 
factor(s) 
0.58 (0.32-1.06) 0.077 
≥65 yrs with no clinical risk 
factor 
0.98 (0.61-1.55) 0.915 
≥65 yrs with clinical risk 
factor(s) 
0.61 (0.41-0.92) 0.018 
 
Male gender 1.43 (1.02-1.99) 0.037 
 
 
 
 
 
Table 4 – Association between pneumococcal serotypes and individuals at risk of 
pneumococcal disease 
 
 
 
 
 
 
 
All values given as n; ‘At-risk’ group defined as those aged 16-64 years with clinical risk factors 
for pneumococcal disease or those aged ≥65 years  
 
Serotype ‘At-risk’ group 
(n=403) 
No risk group 
(n=184) 
OR (95%CI) P value 
1 34 28 0.78 (0.39-1.57) 0.485 
3 21 3 4.50 (1.22-16.56) 0.024 
4 9 7 0.83 (0.28-2.48) 0.734 
5 20 4 3.21 (0.99-10.43) 0.052 
6A/C 19 4 3.05 (0.94-9.95) 0.064 
7F/A 25 44 0.37 (0.18-0.73) 0.004 
8 42 27 Reference  
14 41 9 2.93 (1.23-6.98) 0.015 
19A 27 11 1.58 (0.67-3.70) 0.294 
26 
.2
.4
.6
.8
1
1
.2
0
1
.4
0 1 2 >=3
Number of clinical risks factors for pneumococcal disease
OR Upper CI (95%)/Lower CI (95%)
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Gender and age adjusted odds of PCV-13 serotype CAP with increasing numbers 
of clinical risk factors for pneumococcal infection 
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Figure 2 - Incidence of PCV-13 and non-PCV-13 pneumococcal CAP by age and clinical risk group 
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